Autoimmune therapies aim to inhibit autoreactivity while preserving normal immune function. 31 The transcriptional coregulator OCA-B, also known as Bob.1/OBF-1 (gene symbol Pou2af1) is 32 induced in stimulated naïve CD4 + T cells, where it docks with transcription factor Oct1 to 33 regulate genes such as Il2 and Ifng. OCA-B promotes expression of these targets in cases of 34 repeated antigen exposure, a necessary feature of autoimmunity. Polymorphisms in Ocab itself 35 and binding sites for Oct1/OCA-B complexes are associated with multiple forms of 36 autoimmunity including autoimmune (type-1) diabetes. We hypothesized that T cell-specific 37 OCA-B deletion would protect mice from type-1 diabetes, and that pharmacologic OCA-B 38 inhibition would provide similar protection. We developed an Ocab conditional allele and 39 backcrossed it onto a diabetes-prone NOD/ShiLtJ strain background. T cell-specific OCA-B loss 40 protected mice from spontaneous T1D. Protection was associated with reduced pancreatic T cell 41 and macrophage infiltration and reduced proinflammatory cytokine expression. We profiled 42 prediabetic pancreatic lymph nodes and islets by single-cell RNA sequencing and T cell receptor 43 clonotype analysis. Although lymph nodes showed minimal differences, in the islets CD8 + T cell 44 specificities associated with diabetes pathogenesis failed to emerge in OCA-B deficient 45 activated/memory cells. In contrast, CD4 + clones associated with diabetes were present, but only 46 in anergic cells. The protective effect of OCA-B loss was diminished, or even eliminated, using 47 monoclonal models with high affinity to artificial or neoantigens. Rationally-designed 48 membrane-penetrating OCA-B peptide inhibitors normalized glucose levels, and reduced T cell 49 infiltration and proinflammatory cytokine expression in newly-diabetic NOD mice. Together, the 50 results indicate that OCA-B is a potent autoimmune regulator and a promising target for 51 pharmacologic inhibition. 52 54
Introduction 53
Type 1 Diabetes (T1D) is an autoimmune disease in which the host immune system is directed towards Table 2 ). We also determined TCR repertoires in these T cell populations, identifying few changes as a 144 whole ( Supplementary Fig. 2c ). However, specific sub-populations did show changes in TCR 145 utilization. For example, NOD CD8 + T cells expressing Trbv13-3 (Vb8.1) display reactivity to islet-146 specific glucose-6-phosphatase catalytic subunit related protein (IGRP) and are associated with T1D 21 . 147 Although this clone was unchanged across the entire population of T cells ( Supplementary Fig. 2c ), it 148 was over-represented in the effector CD8 + population ( Supplementary Fig. 2d ). In contrast, other TCR 149 clonotypes such as Trbv13-1, Trbv13-2, Trbv1 and Trbv15 were unchanged (not shown). This result 150 was confirmed with flow cytometric staining of CD8 + T cells using Vb8.1 antibodies (Supplementary 151 Fig. 2e ). This change was coupled with a decrease the presence of this particular clone in pancreatic 152 islets (below). These results indicate that OCA-B loss does not result in gross changes PLN T cell 153 repertoire or status, but results in lymph node retention of potentially autoreactive clones. Fig. 1d ). Blood glucose was stable in Ocab fl/fl Cre CD4 females but began to spike in control mice 161 beginning at week 16, rising to an average of >300 mg/dL by 24 weeks (Fig. 1e ). Similar results were 162 observed using female whole-body knockout NOD.Ocab -/compared to Ocab +/+ littermate controls. 163 While ~80% of control females developed T1D within 24 weeks after birth, only ~20% of 164 NOD.Ocab D/D females did so (Fig. 1f) . Cumulatively, the results show that OCA-B expression in T 165 cells is critical for T1D pathogenesis in NOD mice. annihilated their pool of beta cells, resulting in lack of antigen. We also studied pancreatic 172 macrophages in these mice. Islet infiltration of F4/80 + CD11b + macrophages is critical for NOD T1D 173 pathogenesis both in spontaneous and adoptive transfer T1D models 23, 24 . CCL1 expressed in 174 diabetogenic CD4 T cells is known to recruit CCR8-expressing macrophages 25 . Interestingly, OCA-B 175 deletion in stimulated, rested and re-stimulated CD4 + T cells decreases Ccl1 mRNA expression 176 compared to controls ( Supplementary Table 3 ). We therefore hypothesized that OCA-B expression in 177 T cells is important for macrophage islet infiltration. Despite the fact that antigen and greater numbers 178 of T cells were present, we observed 5-fold fewer macrophages in 24 week-old NOD.Ocab fl/fl Cre CD4 179 islets ( Fig. 2a,b) . In contrast, macrophage numbers were unaffected by T cell-specific OCA-B loss in 180 pre-diabetic (8 week) mice ( Fig. 2a) . 181 IFNg is a direct OCA-B target gene 4 and a strong promoter of T1D. Levels of serum and 182 pancreatic IFNg gradually rise in young NOD mice, reaching maximum at diabetes onset 26 . 183 Diabetogenic CD4 + and CD8 + T cells both express IFNγ in humans and NOD mice 27, 28, 29 . Therefore, 184 we predicted that OCA-B loss would reduce islet IFNg expression in CD4 + and CD8 + T cells. We 185 compared IFNγ-expressing pancreatic CD4 + and CD8 + T cells in female NOD.Ocab fl/fl Cre CD4 and 186 littermate control mice lacking Cre CD4 . In 12 week-old prediabetic mice, CD8 + T cell frequencies were 187 significantly decreased ( Fig. 2c ), whereas CD4 + T cells at the same timepoint were unchanged (data 188 not shown). At the time of diabetes onset (16 weeks), proportionally fewer IFNγ-expressing CD8 + T 189 cells were present in Ocab conditional-deleted mice compared to controls ( Fig. 2d ).
190
CD4 + CD25 HI FoxP3 + Tregs interfere with T1D development in NOD mice 30, 31 . Analysis of 191 previously generated RNAseq datasets shows that naïve Ocab null CD4 + T cells express 4-fold more
Foxp3 mRNA compared to controls upon in vitro stimulation ( Supplementary Table 3 ). To determine 193 whether the protection conferred by T cell conditional OCA-B is associated with changes in Tregs, we 194 analyzed pancreatic Treg frequencies, observing a trend towards more Tregs in pre-diabetic (8 week-195 old) NOD.Ocab fl/fl Cre CD4 mice compared to controls ( Fig. 2e ). Interestingly, there were no differences 196 late in disease course, at 16 or 24 weeks (data not shown).
197
If increased Treg numbers help mediate protection in NOD.Ocab fl/fl Cre CD4 mice, then depletion 198 of these Tregs would be expected normalize T1D pathogenesis in knockout mice relative to controls.
199
Anti-CD25 antibody injection in neonatal NOD mice depletes Tregs (as well as activated T cells), and 200 accelerates T1D onset 32 . Surprisingly, we observed that anti-CD25 antibody-injected 201 NOD.Ocab fl/fl Cre CD4 mice were still protected from T1D development relative to controls, though to a 202 lesser degree than in undepleted mice ( Fig. 2f ). These results support a conclusion that Tregs partly 203 contribute to the T1D protection in mice lacking OCA-B in their T cells. 204 205 T cell-specific OCA-B deletion alters the islet-infiltrating TCR repertoire. We performed 206 scRNAseq and TCR clonotype analysis similar to Supplementary Fig. 2 , but using older (12 week) but 207 still pre-diabetic NOD.Ocab fl/fl Cre CD4 or NOD.Ocab fl/fl littermate control female mice, and using total 208 CD45 + cells isolated from pancreatic islets rather than PLNs. Cells were isolated from four animals per 209 group and combined for microfluidics and sequencing. After filtering, ~6200 knockout and ~3800 210 control cells were identified. Overlaying cell from both genotypes, we used their gene expression 211 profiles to definitively identify multiple cell lineages, including naïve CD4 + + CD8 + T cells, 212 memory/effector CD4 + T cells, memory/effector CD8 + T cells, B cells, macrophages and neutrophils 213 ( Fig. 3a) . The biggest relative change in populations was neutrophils, which decreased from 3.4 to 214 1.4% in conditional knockout islets ( Fig. 3a) . B cells were also decreased, albeit more slightly. These 215 changes were accompanied by an increase in the percentages of CD4 + and CD8 + T cells with naïve 216 phenotypes in conditional knockouts (31.7 vs. 25%). Like endpoint diabetic animals ( Fig. 2a,b ), 217 macrophage numbers were decreased but only slightly. Unlike PLNs, prediabetic islets showed 218 significant changes in gene expression between the two groups ( Fig. 3b ), the strongest of which 219 occurred in neutrophils (e.g., Cxcl2, down), memory/effector CD8 + T cells (Ccl4, Tcrg-v1, Itga, down; 220 Tcrbv1, Trav8n-2, up), NK T cells (Klra2, Lars2, down) and gdT cells (Gzma, Gzmb, Ccl5, down).
221
We also profiled TCR clonality in pancreatic T cells. Across total T cells, few changes were 222 observed ( Supplementary Fig. 3 ), however this was largely to do similar representation in the naïve T revealed sharp differences. For example, polyclonal NOD mice CD8 + T cells expressing Trbv13-3 225 (Vb8.1) display reactivity to IGRP and are associated with T1D 21 . Relative to controls, this clonotype 226 was under-represented in OCA-B deficient effector + memory CD8 + cells (Fig. 3c , 20.9% vs 8.6%).
227
Approximately half of these cells showed reactivity to IGRP206-214 based on tetramer staining (data not 228 shown). Based on this information, we repeated the clonotype analysis, but only using the effector + 229 memory CD8 + T cell cluster. Within this population, dominant TCR clonotypes used by conditional 230 and control T cells were strikingly different ( Fig. 3d ). Clonotype 1 for example corresponds to a TCRa 231 V8N-2 chain paired with TCRb V1 or V15 and has not been associated with T1D. This clonotype was 232 absent in control islets but represented >4% of OCA-B deficient islet CD8 + effector + memory T cells 233 ( Fig. 3d ). Clonotype 1 cells overlaid with both genotypes is shown in Fig. 3e . Clonotype 2 by contrast 234 is associated with the T1D-associated Vb13.3 b chain. This clonotype was strongly represented in 235 controls (>3%) but absent from experimental effector + memory CD8 + cells ( Fig. 3d ). In contrast to To test the hypothesis that OCA-B loss confers protection in simplified systems, we crossed OCA-B 249 deficient mouse models employing TCR transgenes and model antigens. and control NOD.BDC2.5 mice into NOD.Scid recipients also showed no difference between the 257 experimental and control groups ( Supplementary Fig. 4a ). Negative results were also generated by 258 transplanting total CD4 + T cells into immunodeficient NCG recipients ( Fig. 4b ). We also tested the 259 effect of T cell conditional OCA-B deletion in a different strain background, C57BL/6J, using the 260 artificial membranous ovalbumin antigen expressed from the rat insulin promoter (RIP-mOVA) 36 . In 
307
To determine whether OCA-B affects in the protein related to T cell anergy, we harvested pre-308 activated CD4 + CD44 + T cells from the spleens of Ocab fl/fl Cre CD4 and littermate control Cre CD4 animals, 309 and re-stimulated them for 24 hr ex vivo using anti-CD3e antibodies ± co-stimulation using anti-CD28 310 antibodies. CD4 + CD44 + FR4 hi CD73 hi anergic cells were ~2 fold more strongly induced in T cells 311 lacking OCA-B ( Fig. 5d ). ICOS levels were similarly elevated in the OCA-B deficient condition ( Fig.   312 5e). Additionally, and consistent with prior data 5 , the expression of the activation marker CD25 was 313 decreased (Fig. 5f ). These results suggest that OCA-B loss creates a requirement for CD28 co-314 stimulation in secondary stimulation situations, effectively instituting higher immune checkpoint 315 thresholds in order for cells to become fully re-activated. OCA-B residues aligning to AR lie on one side of a short, solvent-exposed alpha-helix ( Fig. 6a ). Glu30 346 (red), Leu31 (yellow), Arg34 (blue) and His38 (blue) may therefore constitute a Jmjd1a docking 347 surface. These residues are conserved to humans (Fig. 6c ). We mutated OCA-B L31 and R34 to Control OVA-fused peptide showed no such effect ( Supplementary Fig. 5 ). We then treated splenic with the larger peptide #3 but not with peptide #1 (not shown). Peptide #1 is missing residues 369 important for the Jmjd1a interaction based on mutagenesis (Fig. 6b ). For all further experiments, we 370 exclusively used the JumOCA peptide. 371 We then synthesized a Tat-conjugated peptide using a scrambled JumOCA sequence. This 372 peptide has the same amino acid composition, mass and pI, but lacks the OCA-B primary amino acid 373 sequence and should not be able to efficiently compete for Jmjd1a. We used the Tat-only, scrambled 374 and JumOCA peptides in assays similar to Fig. 6f , except using flow cytometry to assay endpoint IL-2 375 production. JumOCA significantly inhibited IL-2 production relative to the scrambled control, 376 however there were significant toxicities associated with both the scrambled and Tat-only peptides 377 relative to vehicle (Fig. 6g ). An example mouse from this experiment is shown in Fig. 6h .
378
The above results are consistent with the JumOCA peptide operating through a Jmjd1a 379 competitive inhibition mechanism. To test this directly, we used scrambled, double point mutant and resulting in efficient OCA-B co-IP (Fig. 6i, lane 3) . Incubation of precipitated material with scrambled or double point mutant peptides had no effect on OCA-B co-immunoprecipitation (lanes 4-5), while during which glucose homeostasis can be restored. We treated 14-18 week-old littermate female NOD 390 mice whose glucose levels were newly-risen above 225 mg/dL but still below 275 mg/dL with three 391 intravenous injections of 10 mg/kg peptide or Tat-only peptide control. Injections were spaced 12 hr 392 apart. 12 hr after the final injection, blood glucose was collected and flow cytometry performed on the 393 pancreas and PLNs. Strikingly, the inhibitor reversed elevated blood glucose (Fig. 7a ). Control peptide 394 at the same concentration had no effect. Islet T cell infiltration and pro-inflammatory IFNg and IL-17A 395 cytokine production were strongly reduced by JumOCA peptide treatment compared to controls (Fig.   396 7b,c). In contrast to the pancreas, PLNs showed no change in T cell numbers or percentages (Fig. 7d ) 397 but similar changes in pro-inflammatory cytokine production (not shown). These data provide 398 evidence that targeting OCA-B is a valid strategy to treat emerging T1D, potentially with minimal side 399 effects, and identify a first-generation inhibitor that is efficacious in vivo.
Discussion

401
Here we show that targeting OCA-B genetically or pharmacologically can block T1D in mouse 402 models. OCA-B is a transcriptional coregulatory protein named for its strong expression in the B cell 403 lineage, where it is dispensable until after B cell activation, where it is essential for the generation of protective vs. exacerbating effects in these models may be due to effects on BCR repertoire 65 . T cell-specific knockout of Oct1, a transcription factor with which OCA-B docks, blocks EAE but leaves 434 responses to infection with neurotropic viruses intact 5 . Together these data indicate that in T cells Oct1 435 and OCA-B promote autoimmunity including T1D, but that their role in B cells may be more complex. grinding and passage through 70 µm strainers. CD4 + T cells were isolated using a mouse CD4 + T cell 559 isolation kit (Miltenyi Biotec). Isolated CD4 + T cells were cultured and stimulated with 5 µg/ml plate-560 bound anti-CD3ε (BD Bioscience) and/or 2 µg/ml anti-CD28 antibodies (eBioscience) as described 561 previously 5 . For OCA-B inhibitor peptide treatments, naïve CD4 T cells were isolated from WT 562 C57BL/6 mice using a mouse naïve CD4 + T cell isolation kit (Miltenyi Biotec) and cultured as Histology. Formalin-fixed pancreatic tissues were embedded in paraffin. H&E-stained sections were 633 scored for islet inflammation based on published precedents 77 : 0, sparse surrounding sentinel 634 leukocytes, no insulitis; 1, peri-islet leukocytes; 2, some into islet, <50% of islet area; 3, islet insulitis 635 with >50% of islet area occupied by leukocytes; 4, islets destroyed with fibrotic remnants. 
436
OCA-B is typically expressed ~50-fold higher in B cells compared to T cells. A correctly calibrated
715
Spontaneous T1D was measured in female Ocab -/-(n=20) or control Ocab +/+ (n=12) littermates. h, 716 Naïve CD4 + or CD8 + T cells were isolated from C57BL/6 spleens and stimulated for up to two days in 717 vitro using anti-CD3ε and CD28 antibodies. Cells were then washed and replated in the presence of 718 exogenous IL-2. After 8 days rest in culture, cells were restimulated for 6 hr. Lysates were prepared 719 from each step and subjected to OCA-B immunoblotting to assess changes in expression. Oct1 and b-720 actin are shown as controls. 
